Characteristics of the study participants
. | . | . | CD4 counts, 106 cells/mL . | . | CD8 counts, 106 cells/mL . | . | Viral load, copies/mL . | . | % Gag-specific CFSElow CD3+CD4+ T cells . | . | % CMV-specific CFSElow CD3+CD4+ T cells . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group and subject ID . | Follow-up*time after sc, mo . | AIDS-defining illness . | Early . | Late . | Early . | Late . | Early . | Late . | Early . | Late . | Early . | Late . | |||||
| CTA | |||||||||||||||||
| 57 | 122 | NA | 0.68 | 0.47 | 1.40 | 4.40 | 1 550 | 1 000 | 4.3 | 4.9 | 3.5 | 59.3 | |||||
| 658 | 124 | NA | 1.21 | 0.51 | 0.80 | 1.16 | 450 000 | 24 000 | 2.4 | 4.2 | 1.5 | 3.4 | |||||
| 1160 | 111 | NA | 0.67 | 0.28 | 0.90 | 1.25 | 12 000 | 11 550 | 1.9 | 0.4 | 2.0 | 4.3 | |||||
| 126 | 148 | NA | 0.55 | 0.46 | 1.00 | 1.31 | 1 000 | 110 | 1.0 | 1.0 | 10.8 | 18.8 | |||||
| 44 | 114 | NA | 0.47 | 0.37 | 0.80 | 1.02 | 1 000 | 1 000 | 1.2 | 1.4 | 2.4 | 4.3 | |||||
| 1171 | 82 | NA | 0.77 | 0.44 | 1.70 | 0.86 | 5 000 | 1 000 | 1.7 | 15.4 | 9.2 | 53.3 | |||||
| Median | 118 | NA | 0.68 | 0.47 | 0.95 | 1.21 | 3 275 | 1 000 | 1.8 | 2.8 | 2.9 | 11.6 | |||||
| Progressors | |||||||||||||||||
| 159 | 65 | Pneumocystis carinii | 0.59 | 0.21 | 1.40 | 2.00 | 180 000 | 160 000 | 0.8 | ND | 3.8 | 2.1 | |||||
| 748 | 63 | Microsporidiosis | 0.45 | 0.22 | 0.70 | 0.92 | 160 000 | 100 000 | 1.1 | 1.1 | 30.8 | 20.2 | |||||
| 656 | 60 | Cryptosporidiasis | 0.24 | 0.12 | 0.30 | 0.71 | 52 000 | 25 000 | 8.5 | 0.9 | ND | 14.4 | |||||
| 1211 | 25 | Cryptococcal meningitis | 0.7 | 0.18 | 1.00 | 0.50 | 590 000 | 76 000 | 5.1 | 1.3 | 14.1 | 12.0 | |||||
| 547 | 32 | P carinii | 0.87 | 0.3 | 0.60 | 0.60 | 5 500 | 13 000 | 1.7 | 0.2 | 39.1 | 47.0 | |||||
| 208 | 48 | P carinii | 0.79 | 0.04 | 0.80 | 1.30 | 20 000 | 640 000 | 0.8 | 1.2 | 1.0 | 0.9 | |||||
| 1234 | 57 | P carinii | 0.86 | 0.39 | 1.60 | 1.96 | 33 000 | 360 000 | 1.2 | 0.3 | 12.6 | 8.2 | |||||
| Median | 57 | NA | 0.70 | 0.21 | 0.80 | 0.92 | 52 000 | 76 000 | 1.2 | 1.0 | 13.3 | 12.1 | |||||
. | . | . | CD4 counts, 106 cells/mL . | . | CD8 counts, 106 cells/mL . | . | Viral load, copies/mL . | . | % Gag-specific CFSElow CD3+CD4+ T cells . | . | % CMV-specific CFSElow CD3+CD4+ T cells . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group and subject ID . | Follow-up*time after sc, mo . | AIDS-defining illness . | Early . | Late . | Early . | Late . | Early . | Late . | Early . | Late . | Early . | Late . | |||||
| CTA | |||||||||||||||||
| 57 | 122 | NA | 0.68 | 0.47 | 1.40 | 4.40 | 1 550 | 1 000 | 4.3 | 4.9 | 3.5 | 59.3 | |||||
| 658 | 124 | NA | 1.21 | 0.51 | 0.80 | 1.16 | 450 000 | 24 000 | 2.4 | 4.2 | 1.5 | 3.4 | |||||
| 1160 | 111 | NA | 0.67 | 0.28 | 0.90 | 1.25 | 12 000 | 11 550 | 1.9 | 0.4 | 2.0 | 4.3 | |||||
| 126 | 148 | NA | 0.55 | 0.46 | 1.00 | 1.31 | 1 000 | 110 | 1.0 | 1.0 | 10.8 | 18.8 | |||||
| 44 | 114 | NA | 0.47 | 0.37 | 0.80 | 1.02 | 1 000 | 1 000 | 1.2 | 1.4 | 2.4 | 4.3 | |||||
| 1171 | 82 | NA | 0.77 | 0.44 | 1.70 | 0.86 | 5 000 | 1 000 | 1.7 | 15.4 | 9.2 | 53.3 | |||||
| Median | 118 | NA | 0.68 | 0.47 | 0.95 | 1.21 | 3 275 | 1 000 | 1.8 | 2.8 | 2.9 | 11.6 | |||||
| Progressors | |||||||||||||||||
| 159 | 65 | Pneumocystis carinii | 0.59 | 0.21 | 1.40 | 2.00 | 180 000 | 160 000 | 0.8 | ND | 3.8 | 2.1 | |||||
| 748 | 63 | Microsporidiosis | 0.45 | 0.22 | 0.70 | 0.92 | 160 000 | 100 000 | 1.1 | 1.1 | 30.8 | 20.2 | |||||
| 656 | 60 | Cryptosporidiasis | 0.24 | 0.12 | 0.30 | 0.71 | 52 000 | 25 000 | 8.5 | 0.9 | ND | 14.4 | |||||
| 1211 | 25 | Cryptococcal meningitis | 0.7 | 0.18 | 1.00 | 0.50 | 590 000 | 76 000 | 5.1 | 1.3 | 14.1 | 12.0 | |||||
| 547 | 32 | P carinii | 0.87 | 0.3 | 0.60 | 0.60 | 5 500 | 13 000 | 1.7 | 0.2 | 39.1 | 47.0 | |||||
| 208 | 48 | P carinii | 0.79 | 0.04 | 0.80 | 1.30 | 20 000 | 640 000 | 0.8 | 1.2 | 1.0 | 0.9 | |||||
| 1234 | 57 | P carinii | 0.86 | 0.39 | 1.60 | 1.96 | 33 000 | 360 000 | 1.2 | 0.3 | 12.6 | 8.2 | |||||
| Median | 57 | NA | 0.70 | 0.21 | 0.80 | 0.92 | 52 000 | 76 000 | 1.2 | 1.0 | 13.3 | 12.1 | |||||
For early CD4 counts, P > .999; for late CD4 counts, P = .008; for early CD8 counts, P = .37; for late CD8 counts, P = .46; for early viral load, P = .05; for late viral load, P = .002; for early Gag-specific CFSElow CD3+CD4+ T cells, P = .63; for late Gag-specific CFSElow CD3+CD4+ T cells, P = .13; for early CMV-specific CFSElow CD3+CD4+ T cells, P = .13; and for late CMV-specific CFSElow CD3+CD4+ T cells, P = .63.
ND indicates not done; and NA, not applicable.
Follow-up in months after seroconversion
P values indicate the differences between the 2 groups at each time point (Mann-Whitney)